Navigation Links
Small in Medical Technology

New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects

LEIDEN, The Netherlands, July 6 /PRNewswire/ -- Three new small and medium sized enterprises (SMEs) - Syncom, Synvolux Therapeutics and InteRNA Technologies - have joined public-private partnership TI Pharma by participating in two new projects. These projects, focusing on cancer and inflammat...

Spirus Medical Announces Complete Examinations of the Small Intestine by Physicians Using Endo-Ease(TM)

CHICAGO, May 29 /PRNewswire/ -- Spirus Medical, Inc. ( www.spirusmed.com ), a leading developer of diagnostic and therapeutic advancement systems for gastroenterology, urology and gynecology, announced that physicians using its Endo-Ease(TM) line of devices have performed complete examinations o...

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

SAN DIEGO, May 26 /PRNewswire/ -- TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that Phase 1 clinical results from studies of TRC105 and TRC102 in patients with advanced cancer will be presented at the American S...

Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer

SEATTLE, April 21 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN ) today announced that the Company has enrolled the first patient in a Phase 1 clinical trial of D3263 in patients with advanced cancer. D3263 is Dendreon's lead small molecule drug candidate designed to target TRPM8...

Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., March 25 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that it has reached its enrollment target of 400 patients in the SPEAR (Study of Picoplatin Efficacy After Relapse) tria...

Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.

SAN DIEGO, March 10 /PRNewswire/ -- Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase I clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. The results of Phase I studies are expected to be available in...

Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors

More Than 75 Percent of Patients Diagnosed Have Small Renal Cell Tumors; Safe Interventional Radiology Treatment Shown Near 100 Percent Effective in Destroying Localized Tumors, Says Johns Hopkins Study SAN DIEGO, March 9 /PRNewswire-USNewswire/ -- Freezing kidney tumors -- using a safe mi...

Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents

Journal of American College of Cardiology publishes positive ATLAS clinical data NATICK, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final modules of the Company's...

Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)

SAN CARLOS, Calif., May 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinotecan). The Webcast will include a presentation by featur...

Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit

- Final Safety and Efficacy Data Presented at 1st IASLC-ESMO European Lung Cancer Conference - SOUTH SAN FRANCISCO, Calif., April 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announce...

Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference

SOUTH SAN FRANCISCO, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that data from a Phase 2 trial of picoplatin, the Company's lead product candidate, in patients with small cell ...

CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent

Triggers $22-million Tranche of Venture Capital Funding SUNNYVALE, Calif., March 31 /PRNewswire/ -- CardioMind, Inc., a developer of stents for small, difficult-to-treat blood vessels, announced today that it has begun a First-in-Human clinical trial of its drug-eluting stent. The CARE...

NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference

NEW YORK, Feb. 22 /PRNewswire/ -- NexGenix Pharmaceuticals, presented data on its Hsp90 inhibitor program today at the GTCBio 5th Annual Cancer Drugs Research & Development Conference taking place in Phoenix, Arizona. The company presented data on NXD30001, one of several novel, radicicol-base...

Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells

WASHINGTON, Feb. 5 /PRNewswire-USNewswire/ -- Researchers are identifying innovative therapeutics for sickle cell anemia that focus on specific factors in the disease's progression, such as the important role of hydration of the red blood cells. According to a study prepublished online in Bloo...

XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis

VALLEY COTTAGE, N.Y., Dec. 10 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , TASE: XTL) announced today that it will make two scientific presentations related to its pre-clinical Hepatitis C virus (HCV) small molecule program at HEP DART 2007, an international scientifi...

Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

Interim analysis of Phase 2 clinical data presented at the 2007 Chemotherapy Foundation Symposium BOULDER, Colo., Nov. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) today released interim findings from its Phase 2 trial of Amrubicin in second-line chem...

Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies

Enrollment temporarily suspended until approval of amendments, which may include adjustments in dosing for certain subpopulations TOKYO, Japan and INDIANAPOLIS, Oct. 24 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY ) today an...

Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer

BOULDER, Colo., Oct. 17 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lun...

AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer

NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB) has identified and filed a patent application on small molecules that are potent inhibitors of the Id proteins. "The identification of these lead molecules and the filing of this patent constitute major m...

GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer

First FDA Approved Oral Therapy Will Allow Patients to be Treated for This Aggressive Cancer at Home PHILADELPHIA, Oct. 15 /PRNewswire-USNewswire/ -- GlaxoSmithKline (NYSE: GSK) announced today approval by the U.S. Food and Drug Administration (FDA) for oral HYCAMTIN(R) (t...

Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer

- Phase 2 Median Overall Survival Confirmed and Extended at the 12th World Conference on Lung Cancer in Seoul - SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today ...

Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients

- Results Presented at 12th World Conference on Lung Cancer in Seoul - SOUTH SAN FRANCISCO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that updated results of its Phase 2 clinical t...

Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer

SOUTH SAN FRANCISCO, Calif., Aug. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced that it will present updated results from its Phase 2 trial of picoplatin, including one-year survival data, during a ...

FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer

ROCKVILLE, Md., April 21, 2007-Genentech and FDA notified healthcare professionals of important new safety information regarding tracheoesophageal (TE) fistula formation in a recent clinical study in patients with limited-stage small cell lung cancer (SCLC). This multicenter, non-randomized, singl...

Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting

-- Data from Picoplatin Phase 1 Colorectal and Prostate Cancer Trials To Be Published in 2007 ASCO Proceedings -- SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that data from a Ph...

Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer

NEW HAVEN, Conn., June 04, 2007 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. announced that it presented updated clinical data in a poster session at the 43rd Annual Meeting of The American Society of Clinical Oncology (ASCO) on its lead anticancer agent Cloretazine(R) (VNP40101M) as a sin...

Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer

Interim Analysis of Phase 2 Clinical Data Published at the American Society of Clinical Oncology 43rd Annual Meeting CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation today released interim findings from its Phase II, multi-center clinical study of Amrubicin, the company's thir...

Prothrombin Time Comes in Small (CLIA-Waived) Packages

Determining prothombin levels is necessary to plan or evaluate anticoagulant therapy, to diagnose various inherited conditions, such as hyperhomocystinemia, elevated factor VIII levels, dysfibrinogenemia, factor XII deficiency and disorders of plasmin generation, and to assess acquired conditions,...

Bench-Top Centrifuges--Basic Tools for the Small Lab

No matter how elementary or advanced, every clinical laboratory possesses one essential devicea centrifuge. It may be a bench-top or floor model, refrigerated or non-cooled, but this apparatus, because of its unique ability to fractionate liquid specimens by creating spin-induced high g-forces, ha...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

... the eye. The tiny cup administers the drug slowly by passive diffusion through the sclera, where it reaches the retina and vitreous. The device is so small the patient should feel little or no discomfort and it does not hinder normal vision. Currently, drugs for most retinal diseases are delivered ...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

...major depression at some time in their lives. About Labopharm Inc. Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now ...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...prietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative o...etration across the blood-brain barrier, an important potential advance for small molecule therapies. The product is being developed to treat opioid-induced ...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...inical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's mo...y technology, TRAP((R)), which enables the rapid and efficient discovery of small molecule drug candidates. TELIK, the Telik logo, TELINTRA, TELCYTA a...

John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden

...lages in Ghana and Tanzania. The non-profit's mission is to end poverty around the world through sustainable development at the individual, family and small community levels. Go to http://www.showmecampaign.org/ for more information. About Gap Inc. Gap Inc. is a leading global specialty r...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

...ination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Ro...

Is Your Hair Taking a Break?

...ect men and women, alopecia areata, occurs when the body's white blood cells attack the hair follicles and put them to sleep. This results in either a small patch of complete hair loss on the scalp that may be easy to cover or complete hair loss on the scalp (similar to the effects of chemotherapy in cance...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

...ment company leading the scientific research of neurogenesis by applying its robust and proprietary platform technology to identify novel pathways for small molecule therapeutics to treat various central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous stem cells in the adult ...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

..._arthritis . About Rigel ( www.Rigel.com ) Rigel is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signalin...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

...hypercorticism (an excess level of steroids in your body) or adrenal insufficiency (your adrenal gland cannot produce enough steroids) may appear in a small number of patients, particularly when ASMANEX is administered at higher than recommended doses over prolonged periods of time. If such effects occur, ...

July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair

...ously looking for the good in life, being grateful, looking for pleasure in small things or practicing random acts of kindness. Other people may need treatme... heart valve surrounded by an expanding wire mesh (stent) can be placed via small incisions without stopping the heart. The device is placed via a slender tu...
Other Tags
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
(Date:12/3/2014)... Dec. 2, 2014 As part of our ... Technologies is pleased to announce the release of a ... to collect the workforce data that they need. ... been left by existing readers. Many such devices have ... and modern technology. Older models force users to navigate ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... Dylan Queen, a famous online company supplying women’s special ... prom dresses, most of which are priced under $200. ... the promotion is valid until Jan. 22, 2015; the ... market. , The prom dresses in this new collection ... strapless, empire strapless chiffon, one shoulder, floor-length, V-neck beading, ...
(Date:12/25/2014)... When head lice hits a home or school, parents and ... of it while keeping it from taking over the house ... solution right in their neighborhood: Lice Troopers . Expanding ... spectrum head lice screening and treatment services to families and ... Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , The ...
(Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
(Date:12/25/2014)... Aliso Viejo, California (PRWEB) December 25, 2014 ... the release of ProFire 5k. A fully customizable business ... X . , “Adding the ProFire 5k business tool, ... style” Said Christina Austin, CEO of Pixel Film Studios. ... the look and style to add professionalism to a ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
Other Contents